MARKET

ALXO

ALXO

ALX ONCOLOGY HOLDINGS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

61.51
+0.37
+0.61%
After Hours: 61.51 0 0.00% 16:00 08/03 EDT
OPEN
60.57
PREV CLOSE
61.14
HIGH
62.01
LOW
59.58
VOLUME
422.87K
TURNOVER
--
52 WEEK HIGH
117.45
52 WEEK LOW
30.06
MARKET CAP
2.14B
P/E (TTM)
-30.1860
1D
5D
1M
3M
1Y
5Y
Dosing underway in ALX Oncology/Merck's mid-stage ASPEN-04 study for head and neck cancer
ALX Oncology Holdings (ALXO) in partnership with Merck (MRK) announce the first patient has been dosed in the Phase 2 ASPEN-04 study evaluating the combination of ALX148, a next generation
Seekingalpha · 6d ago
BRIEF-Alx Oncology Announces First Patient Dosed In Aspen-04
reuters.com · 6d ago
ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA(R) (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, in partnership with Merck, known as MSD outside the United States and Canada, today announced...
GlobeNewswire · 6d ago
Alx Oncology Holdings Inc (ALXO) President & CEO Jaume Pons Sold $911,319 of Shares
GuruFocus News · 07/20 06:16
ALX Oncology Holdings Inc. (ALXO) Upgraded to Buy: Here's What You Should Know
ALX Oncology Holdings Inc. (ALXO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 07/15 16:00
Read This Before Selling ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Simply Wall St. · 07/15 05:36
ALX Oncology (ALXO) Sees Hammer Chart Pattern: Time to Buy?
ALX Oncology (ALXO) has been struggling lately, but the selling pressure may be coming to an end soon.
Zacks · 07/12 10:07
Biotech M&A may heat up with potential targets Horizon Therapeutics, Arrowhead Pharma, analyst says
janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to
Seekingalpha · 07/11 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALXO. Analyze the recent business situations of ALX ONCOLOGY HOLDINGS INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALXO stock price target is 97.29 with a high estimate of 103.00 and a low estimate of 85.00.
EPS
Institutional Holdings
Institutions: 94
Institutional Holdings: 33.52M
% Owned: 96.55%
Shares Outstanding: 34.71M
TypeInstitutionsShares
Increased
46
3.35M
New
16
222.59K
Decreased
18
1.66M
Sold Out
10
688.06K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.43%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Chairman/Executive Director
Corey Goodman
President/Chief Executive Officer/Director
Jaume Pons
Chief Financial Officer
Peter Garcia
Chief Accounting Officer/Vice President - Finance
Shelly Pinto
Other/Director
Sophia Randolph
Independent Director
Rekha Hemrajani
Independent Director
Jason Lettmann
Independent Director
Jack Nielsen
Independent Director
Graham Walmsley
No Data
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on enabling patients to fight cancer by developing therapies that block the cluster of differentiation 47 (CD47) checkpoint pathway and bridge the innate and adaptive immune system. The Company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, ALX148, is a CD47 blocking therapeutic. ALX148 is a fusion protein that combines a CD47 binding domain with its inactivated fragment crystallizable (Fc) domain. The CD47 binding domain of ALX148 is an affinity enhanced extracellular domain of signal regulatory protein alpha (SIRPa), a protein that is the natural receptor to CD47 found on myeloid cells. Its programs are focused on targeting CD47 across various oncology indications.

Webull offers kinds of ALX Oncology Holdings Inc stock information, including NASDAQ:ALXO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALXO stock methods without spending real money on the virtual paper trading platform.